Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: N/A
• EPS Growth: 7.57%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -2.32
• Shares Outstanding: 57,342,846
• 10 Day Avg. Volume: 1,566,626
• 30 Day Avg. Volume: 1,084,939
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 62.00
• Price to Cash Flow (P/CF): -8.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $83.88
• Price Target Upside: 263.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Structure Therapeutics, Inc.'s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.

Positive Factors

Competitive Landscape

Pfizer's decision not only removes a competitor from the oral GLP-1 race but also creates a strategic opening for later-stage assets to become potential M&A targets, particularly those with clean hepatic safety profiles like Structure Therapeutics’ aleniglipron.

Financial Stability

The company has a substantial cash balance of $883.5M, expected to fund operations through at least 2027.

Market Penetration

Differentiation of aleniglipron is key in terms of better pharmacodynamics and safety for eventual success and market penetration as the next-gen oral drug.

Negative Factors

Adverse Events

Questions remain around GIPR antagonism as a mechanism of action, with limited transparency around GI-related adverse events.

Competition

The price target for GPCR has been lowered from $93 to $60 due to increased competition.

Stock Performance

GPCR shares have sagged of late.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics, Inc. generates revenue through the development and commercialization of its drug candidates. The company makes money by advancing its compounds through clinical trials and seeking regulatory approval for market entry. Once approved, these drugs can be licensed or sold to pharmaceutical companies or healthcare providers, generating income through sales, royalties, or milestone payments. Additionally, the company may engage in strategic partnerships or collaborations with other biopharmaceutical firms, which can provide funding, shared resources, and expertise in exchange for a share in the profits or rights to market the developed therapies. These partnerships and collaborations often play a significant role in the company's revenue model, offering both financial support and expanded market reach.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Structure Therapeutics is in a typical biotechnology growth phase with heavy reliance on external financing to support operations and R&D, evident from zero revenues and increasing losses. While the balance sheet shows strong liquidity due to financing, the absence of operating income and negative cash flows underscore financial sustainability risks. Investors must consider the company's future ability to generate revenue and control costs as it progresses through its development pipeline.

Income Statement

The company has consistently reported zero revenue over the analyzed periods, indicating a lack of commercial product or service sales, typical for early-stage biotech firms. Net losses have widened significantly from $15,876 in 2020 to $122,526,000 in 2024, showing increased expenses likely related to R&D and operational scaling. This trajectory signals an aggressive investment phase with high cash burn without immediate income generation.

Balance Sheet

The balance sheet shows strong cash positions with cash and equivalents increasing from $37,445 in 2020 to $883,518,000 in 2024, largely due to financing activities, which is crucial for the company's operations given the lack of revenue. The debt-to-equity ratio has improved as equity turned positive in recent years, but total debt remains low compared to equity, indicating low leverage. However, the negative historical equity values raise concerns about prior financial stability.

Cash Flow

Operating cash flow remains negative, reflecting the company's ongoing investment in R&D and operations without corresponding income. Free cash flow is consistently negative, indicating continued cash burn. The company relies heavily on financing activities to fund operations, as evidenced by significant cash inflows from financing. This dependency poses a risk if future financing rounds are not successful.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-949.17K	-623.26K	-266.35K	-20.03K
	EBIT
-158.23M	-102.78M	-52.56M	-37.70K	-15.91K
	EBITDA
-158.23M	-102.46M	-52.28M	-37.62M	-15.75M
	Net Income Common Stockholders
-122.53M	-89.62M	-51.32M	-38.05K	-15.88K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
883.52M	467.32M	90.84M	107.31K	37.45K
	Total Assets
903.33M	482.02M	97.84M	111.16K	38.70K
	Total Debt
3.86M	5.45M	260.00K	621.00	280.00
	Net Debt
-165.65M	-124.34M	-90.58M	-104.68K	-16.07K
	Total Liabilities
38.49M	29.05M	212.99M	175.89K	61.17K
	Stockholders Equity
864.84M	452.97M	-115.14M	-64.73K	-22.47K
Cash Flow		Free Cash Flow
-117.93M	-81.66M	-46.27M	-33.37K	-14.30K
	Operating Cash Flow
-116.64M	-79.49M	-46.12M	-32.16K	-14.28K
	Investing Cash Flow
-358.91M	-268.34M	-62.11M	17.86K	-21.15K
	Financing Cash Flow
515.26M	451.53M	29.01M	103.25K	25.84K

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 23.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Neutral. The current price of 23.1 is above the 20-day moving average (MA) of 18.03, above the 50-day MA of 20.63, and below the 200-day MA of 31.81, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 63.85 is Neutral, neither overbought nor oversold. The STOCH value of 85.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WVE	51 Neutral	$939.33M	―	-73.24%	―	-4.42%	-42.17%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
NRIX	47 Neutral	$873.66M	―	-64.16%	―	-30.25%	-5.92%
DYN	44 Neutral	$1.13B	―	-88.03%	―	―	14.93%
ETNB	42 Neutral	$915.32M	―	-78.34%	―	―	-70.45%
ELVN	36 Underperform	$794.85M	―	-32.04%	―	―	12.85%
GPCR	31 Underperform	$1.32B	―	-18.61%	―	―	7.57%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics Advances Obesity Treatment Candidate

Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.